- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | eXoZymes reports Q2 results | 1 | Seeking Alpha | ||
| 20.08. | eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today | 553 | ACCESS Newswire | Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes... ► Artikel lesen | |
| 18.08. | exoZymes reports 10-fold productivity gain in NCT manufacturing | 1 | Investing.com | ||
| 18.08. | eXoZymes meldet zehnfache Produktivitätssteigerung bei der NCT-Herstellung | 1 | Investing.com Deutsch | ||
| 18.08. | eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets | 385 | ACCESS Newswire | Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing.Estimated manufacturing cost equivalent has... ► Artikel lesen | |
| 13.08. | EXOZYMES INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 | 476 | ACCESS Newswire | Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar... ► Artikel lesen | |
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 23.07. | eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing | 485 | ACCESS Newswire | Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.The 9-month project awarded... ► Artikel lesen | |
| 26.06. | eXoZymes erhält 2 Millionen US-Dollar vom NIH zur Weiterentwicklung von Cannabinoid-Analoga für die Arzneimittelforschung | 1 | Bionity.com | ||
| 26.06. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 24.06. | Cannabinoid-Forschung: eXoZymes sichert sich NIH-Zuschuss über 2 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 24.06. | exoZymes receives $2M NIH grant for cannabinoid research | 1 | Investing.com | ||
| 24.06. | eXoZymes awarded $2M NIH Grant to advance cannabinoid analogs for drug discovery | 2 | Seeking Alpha | ||
| 24.06. | eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery | 426 | ACCESS Newswire | Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new... ► Artikel lesen | |
| 17.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | eXoZymes schließt Kapitalerhöhung über 5,95 Mio. US-Dollar ab | 2 | Investing.com Deutsch | ||
| 17.06. | eXoZymes closes $5.95M public offering of stock and warrants | 1 | Investing.com | ||
| 17.06. | eXoZymes Inc. Announces Closing of $6 Million Public Offering | 493 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 08.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | eXoZymes prices $5.33M public offering of stock and warrants | 3 | Seeking Alpha |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,240 | -0,38 % | Dividendenbekanntmachungen (03.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADMIRAL GROUP PLC GB00B02J6398 0,705 GBP 0,8204 EUR AEGON LTD ADR US0076CA1045 0,2455 USD 0,2118 EUR AMCOR PLC CDIS AU000000AMC4 0... ► Artikel lesen | |
| EDITAS MEDICINE | 2,570 | -6,88 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,880 | -0,53 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,944 | +2,00 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 5,355 | +0,37 % | Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes | Repurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG... ► Artikel lesen | |
| DENALI THERAPEUTICS | 19,200 | +0,08 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,161 | -5,38 % | Coherus Oncology, Inc.: Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights | - Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets - - Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,221 | +0,69 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,080 | -2,44 % | Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis | First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated... ► Artikel lesen | |
| FAETH THERAPEUTICS | 34,000 | +4,94 % | XFRA 4070: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYBIN | 10,340 | -1,15 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
| ESPERION | 2,709 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.07.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 13.07.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.07.2026ISIN NameCA05337L3048 AVALON... ► Artikel lesen | |
| CAPRICOR | 8,100 | +0,02 % | Capricor wins another upgrade on Deramiocel review extension | ||
| CODEXIS | 1,260 | +0,56 % | Codexis, Inc.: Codexis Reports Second Quarter 2026 Financial Results | Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO... ► Artikel lesen | |
| CORMEDIX | 7,070 | -2,54 % | CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | - Q2 2026 Consolidated Revenue of $101.9 million - - Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million - - Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance... ► Artikel lesen |
Das Unternehmen EXOZYMES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,730 Euro und damit -3,58 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.